柴芍六君子汤加减联合西药治疗慢性肾衰竭临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R692.5

基金项目:

浙江中医药大学校级科研项目(2022FSYYZY24)


Clinical Study on Modified Chaishao Liujunzi Decoction Combined with Western Medicine for Chronic Renal Failure
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察柴芍六君子汤加减联合西药治疗慢性肾衰竭的临床疗效。方法:选取2022年3月— 2024年1月温州市中医院收治的慢性肾衰竭患者132例,采用随机数字表法分为观察组和西药组各66例。西药 组给予西药对症治疗,观察组在西药组基础上予柴芍六君子汤加减治疗。2组均治疗3个月。比较2组治疗前 后炎症因子[白细胞介素-6 (IL-6)、24 h尿蛋白定量和C-反应蛋白(CRP)]、毒素清除率[β2微球蛋白、 甲状旁腺激素(PTH) 和血磷]、肾功能[血尿素氮(BUN) 和血肌酐(SCr)] 水平及中医证候评分,观察不 良反应发生情况。结果:治疗后,2组血清IL-6、24 h尿蛋白定量、CRP含量较治疗前降低(P<0.05),且观 察组血清IL-6、24 h尿蛋白定量、CRP含量均低于西药组(P<0.05)。观察组血β2微球蛋白、PTH和血磷等毒 素清除率均高于西药组(P<0.05)。治疗后,2组BUN、SCr水平较治疗前降低(P<0.05),且观察组BUN、 SCr水平均低于西药组(P<0.05)。治疗后,2组各项中医证候评分较治疗前降低(P<0.05),且观察组各项中 医证候评分低于西药组(P<0.05)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:柴芍 六君子汤加减联合西药治疗能有效降低慢性肾衰竭患者炎症因子和尿蛋白水平,提高毒素清除率,改善肾功 能,且安全性高。

    Abstract:

    Abstract: Objective: To observe the clinical efficacy of modified Chaishao Liujunzi Decoction combined with western medicine in the treatment of chronic renal failure. Methods:A total of 132 patients with chronic renal failure admitted to Wenzhou Hospital of Traditional Chinese Medicine from March 2022 to January 2024 were randomly divided into the observation group and the western medicine group,with 66 cases in each group,using a random number table method. The western medicine group received symptomatic treatment with western medicine, while the observation group received modified Chaishao Liujunzi Decoction on the basis of the western medicine group. Both groups were treated for three months. Compared the levels of inflammatory factors [interleukin-6 (IL-6),24-hour urinary protein quantification and C-reactive protein (CRP)],toxin clearance rates [β2-microglobulin,parathyroid hormone (PTH) and serum phosphorus], renal function [blood urea nitrogen (BUN) and serum creatinine (SCr)], and traditional Chinese medicine syndrome scores before and after treatment in the two groups,and observed the occurrence of adverse reactions. Results:After treatment,the levels of serum IL-6,24-hour urinary protein quantification,and CRP in both groups were decreased when compared with those before treatment (P<0.05),and the levels of serum IL-6,24- hour urinary protein quantification, and CRP in the observation group were lower than those in the western medicine group (P<0.05). The toxin clearance rates of such as β2-microglobulin, PTH, and serum phosphorus in the observation group were higher than those in the western medicine group (P<0.05). After treatment,the levels of BUN and SCr in both groups were decreased when compared with those before treatment (P<0.05),and the levels of BUN and SCr in the observation group were lower than those in the western medicine group (P<0.05). After treatment,the scores of various traditional Chinese medicine syndromes in both groups were decreased when compared with those before treatment (P<0.05),and the scores of various traditional Chinese medicine syndromes in the observation group were lower than those in the western medicine group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: The modified Chaishao Liujunzi Decoction combined with western medicine treatment can effectively reduce the levels of inflammatory and urinary protein in patients with chronic renal failure, improve toxin clearance rates, improve renal function, and has high safety.

    参考文献
    相似文献
    引证文献
引用本文

项方家,陈念昭,陈宇,吴睿轩,徐良仕.柴芍六君子汤加减联合西药治疗慢性肾衰竭临床研究[J].新中医,2025,57(7):83-87

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-04-09
  • 出版日期:
文章二维码